RCKT - Rocket Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
19.30
+1.44 (+8.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close17.86
Open18.15
Bid12.51 x 2900
Ask0.00 x 1100
Day's Range17.80 - 20.02
52 Week Range10.75 - 25.96
Volume512,096
Avg. Volume271,782
Market Cap957.558M
Beta (3Y Monthly)2.74
PE Ratio (TTM)N/A
EPS (TTM)-1.89
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.80
Trade prices are not sourced from all markets
  • Business Wire6 days ago

    Rocket Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces the closing of its previously announced underwritten public offering of 5,175,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 675,000 additional shares of its common stock, at a public offering price of $17.50 per share. Rocket intends to use the net proceeds from this offering to further fund the development of its pipeline of gene therapies for rare diseases, to accelerate the buildout of in-house manufacturing capabilities, and for general corporate purposes. SVB Leerink, Evercore ISI and William Blair acted as joint-bookrunning managers for the offering.

  • Benzinga8 days ago

    The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...

  • Business Wire8 days ago

    Rocket Pharmaceuticals Prices Public Offering of Common Stock

    Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $17.50 per share. Rocket has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock. All the shares in the offering are to be sold by Rocket.

  • Business Wire9 days ago

    Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that it has commenced an underwritten public offering of shares of its common stock. Rocket also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. All the shares in the offering are to be sold by Rocket.

  • Business Wire9 days ago

    Rocket Pharmaceuticals Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting

    - 4 oral presentations and 3 poster presentations focus on Rocket’s clinical and preclinical programs -

  • Business Wirelast month

    Rocket Pharmaceuticals Announces Presentations at the American College of Cardiology 2019 Annual Meeting

    Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces one oral poster presentation and two poster presentations at the upcoming American College of Cardiology 2019 Annual Meeting being held March 16-18, 2019 in New Orleans, LA. RP-A501 is the Company’s first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease that is in development under a collaboration with the University of California San Diego School of Medicine (UCSD). UCSD Health will be the initial and lead center for the planned Phase 1 clinical trial.

  • Are Insiders Selling Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock?
    Simply Wall St.last month

    Are Insiders Selling Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share pricesRead More...

  • Business Wirelast month

    Rocket Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of RP-L102 in the U.S.

    Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that the first patient has been dosed in the open-label, Phase 1 clinical trial of RP-L102, the Company’s lentiviral vector (LVV)-based gene therapy for the treatment of Fanconi Anemia (FA). The clinical trial will evaluate “Process B” RP-L102 which incorporates a modified cell enrichment process, transduction enhancers, and commercial-grade vector manufacturing and cell processing.

  • Business Wirelast month

    Rocket Pharmaceuticals Sponsors Clinical Trial at University of California, Los Angeles (UCLA)

    Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces a research agreement to support the clinical development of Rocket’s lentiviral vector (LVV)-based gene therapy programs in Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO) towards registrational trials. Rocket’s LVV-based gene therapy program for LAD-I, RP-L201, is in clinical development with Rocket’s European partners at the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT).

  • Business Wire2 months ago

    Rocket Pharmaceuticals Reports Full Year 2018 Financial Results and Operational Highlights

    - Three Rocket-sponsored Gene Therapy INDs Across Two Platforms Cleared in Three Months -

  • Business Wire2 months ago

    Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

    Rocket Pharmaceuticals, Inc. , a leading U.S.-based multi-platform gene therapy company, today announces participation at the following upcoming industry co

  • Business Wire2 months ago

    Rocket Pharmaceuticals Recognizes Rare Disease Day® 2019

    Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today commemorates Rare Disease Day®, a day devoted to elevating public understanding of rare diseases and calling attention to the special challenges faced by patients and families. Over 7,000 rare diseases have been identified worldwide. “Our team at Rocket is motivated everyday by our goal of advancing potentially curative gene therapy treatment options on behalf of the pediatric patients and families suffering from devastating, monogenic rare diseases,” said Kinnari Patel, Pharm.D., MBA, Chief Operating Officer and Executive Vice President, Development, of Rocket.

  • Business Wire2 months ago

    Rocket Pharmaceuticals Announces Publication of Comprehensive Review of Danon Disease Cases in the International Journal of Cardiology

    Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces the online publication of a comprehensive literature review of published Danon disease cases in the International Journal of Cardiology, co-authored by Eric Adler, M.D., Director of Cardiac Transplant and Mechanical Circulatory Support at UC San Diego Health and Professor of Medicine at University of California San Diego School of Medicine. The manuscript entitled, “Danon Disease: Gender Differences in Presentation and Outcomes” outlines a comprehensive review of 83 published manuscripts describing cases of Danon disease, the target indication for RP-A501.

  • Business Wire2 months ago

    Rocket Pharmaceuticals Announces Participation in Fireside Chat at the 8th Annual SVB Leerink Global Healthcare Conference

    Rocket Pharmaceuticals, Inc. , a leading U.S.-based multi-platform gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York City.

  • Business Wire3 months ago

    Rocket Pharmaceuticals Announces Clearance of IND for RP-A501 Gene Therapy for Danon Disease

    Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces the clearance of the Company’s Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for RP-A501. RP-A501 is the Company’s first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease that is in development under a collaboration with the University of California San Diego School of Medicine.

  • Business Wire4 months ago

    Rocket Pharmaceuticals to Join NASDAQ Biotechnology Index

    Rocket Pharmaceuticals, Inc. , a leading U.S.-based multi-platform gene therapy company, today announces that the Company has been selected for addition to the NASDAQ Biotechnology Index® .

  • Benzinga5 months ago

    Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'

    With more and more genetic medicine companies going commercial, Leerink turned its attention to the sector this week.  The Analyst Leerink’s Mani Foroohar initiated coverage of 10 genetic medicine companies ...

  • Rocket Pharmaceuticals (RCKT) in Focus: Stock Moves 7.2% Higher
    Zacks5 months ago

    Rocket Pharmaceuticals (RCKT) in Focus: Stock Moves 7.2% Higher

    Rocket Pharmaceuticals (RCKT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Business Wire5 months ago

    Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations for RP-L102 Gene Therapy for Fanconi Anemia

    Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to RP-L102, the Company’s lentiviral vector (LVV)-based gene therapy for the treatment of Fanconi Anemia (FA). RMAT designation was granted based on the positive efficacy and safety results from the ongoing Phase 1/2 clinical trial of RP-L102 being conducted in Europe.

  • Business Wire5 months ago

    Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome

    Rocket Pharmaceuticals, Inc. (RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced it is developing its first adeno-associated viral vector (AAV)-based gene therapy, RP-A501, that is designed to restore the lysosome-associated membrane glycoprotein 2 (LAMP-2) gene which is defective in patients afflicted with Danon disease. RP-A501 is in development under a collaboration led by Dr. Eric Adler, Director of Cardiac Transplant and Mechanical Circulatory Support at UC San Diego Health and Professor of Medicine at University of California San Diego School of Medicine. “Danon disease is a devastating multisystemic disorder that typically leads to death in patients from progressive heart failure in their teens and twenties.

  • Business Wire5 months ago

    Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector

    Rocket Pharmaceuticals, Inc. (RCKT), a leading U.S.-based multi-platform gene therapy company, and REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an exclusive, worldwide license agreement for Rocket to develop and commercialize gene therapy treatments for Danon disease using REGENXBIO’s NAV AAV9 vector, as well as exclusive options for two additional NAV AAV vectors for the treatment of Danon disease.

  • PR Newswire5 months ago

    REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector

    ROCKVILLE, Md. and NEW YORK, Nov. 26, 2018 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, and Rocket Pharmaceuticals, Inc. (RCKT), a leading U.S.-based multi-platform gene therapy company, today announced an exclusive, worldwide license agreement for Rocket to develop and commercialize gene therapy treatments for Danon disease using REGENXBIO's NAV AAV9 vector, as well as exclusive options for two additional NAV AAV vectors for the treatment of Danon disease.